



**TBVI**

TuBerculosis Vaccine Initiative

## New Vaccines to move to a TB free world

**Every second someone worldwide is infected with the bacterium that causes tuberculosis (TB)** and at risk of developing the disease. Every year around 9 million new cases are recorded and almost 2 million people die of TB, equaling one death every 18 seconds. Or imagine, a jumbo jet crashing every 2 hours.

**Current measures to control TB are hampered** by a lack of funding, the increasing emergence of drug resistant bacteria, and HIV/TB co-infection. TB is a leading killer among people living with HIV. Multidrug resistant (MDR) and extensively drug resistant (XDR) TB threaten to undermine TB control efforts in both developed and developing nations. The burden of TB, affecting economies worldwide, is estimated at hundreds of billions of dollars annually.

**The development of faster diagnostics, better drugs and more effective, safe vaccines is urgently needed.** Studies show that without new vaccines TB can never be eliminated. BCG, the only available TB vaccine, protects poor or variable at best against adult pulmonary (lung) TB – the most common form of TB.

**The world needs new vaccines** that boost the BCG vaccine as well as new priming vaccines to replace BCG. These new vaccines should also prevent TB in people with a latent or 'sleeping' TB infection and be safe in people living with HIV.



**TuBerculosis Vaccine Initiative (TBVI), an independent nonprofit organization,** wants to develop these vaccines to protect future generations. TBVI financially and practically supports an integrated European network of more than 40 of the best universities, institutes and industries to develop more effective, safe vaccines.

**By linking the greatest expertise** TBVI is increasing the likelihood of finding the best solutions. Research done by TBVI's network has already resulted in new vaccine discoveries, discoveries in vaccine enhancing adjuvants, and new biomarkers for monitoring clinical trials.

**TBVI aims to raise 200 million euros** over the next ten years to bring 8 vaccines to phase II of clinical trials, to deliver 3 biomarkers that will offer tools to validate vaccines quicker and more precisely, and to improve trial capacity for evaluating TB vaccines.

**Access and affordability of TB vaccines** for the developing world are a statutory objective of TBVI and a commitment that is part of each agreement for support. TBVI leaves the ownership for each candidate TB vaccine with the individual partners, creating freedom to operate and establish partnerships for (late) clinical development.

**TBVI's unique network and outstanding track record** shows that new effective, safe vaccines can be developed. TBVI cooperates with other advocates to mobilize world leaders to commit to tuberculosis. If, collectively, we can leverage the resources of public, private, academic and philanthropic sectors, we can achieve our mission to eliminate TB.

